Tag Archives: Cory Kasimov

Moderna Inc (MRNA) Receives a Buy from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Moderna Inc (MRNA – Research Report) on September 12. The company’s shares closed last Monday at $16.71. According to TipRanks.com, Kasimov is a 4-star analyst with an average return of

ACADIA Pharmaceuticals Inc (ACAD) Gets a Buy Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on ACADIA Pharmaceuticals Inc (ACAD – Research Report) yesterday. The company’s shares closed last Monday at $38.85, close to its 52-week high of $43.98. According to TipRanks.com, Kasimov is a 3-star

Amgen Inc (AMGN) Gets a Hold Rating from J.P. Morgan

In a report issued on August 30, Cory Kasimov from J.P. Morgan maintained a Hold rating on Amgen Inc (AMGN – Research Report). The company’s shares closed last Monday at $208.62, close to its 52-week high of $211.90. According to

J.P. Morgan Sticks to Their Hold Rating for Amgen Inc (AMGN)

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Amgen Inc (AMGN – Research Report) yesterday. The company’s shares closed last Monday at $205.41, close to its 52-week high of $211.90. According to TipRanks.com, Kasimov is a 3-star analyst

J.P. Morgan Keeps Their Sell Rating on Puma Biotechnology (PBYI)

J.P. Morgan analyst Cory Kasimov maintained a Sell rating on Puma Biotechnology (PBYI – Research Report) on August 8 and set a price target of $13. The company’s shares closed on Friday at $11.16, close to its 52-week low of

Jounce Therapeutics Inc (JNCE) Gets a Sell Rating from J.P. Morgan

In a report issued on August 7, Cory Kasimov from J.P. Morgan maintained a Sell rating on Jounce Therapeutics Inc (JNCE – Research Report). The company’s shares closed on Friday at $4.20. According to TipRanks.com, Kasimov is a 4-star analyst